Mitochondrial Adaptation in Nonalcoholic Fatty Liver Disease: Novel Mechanisms and Treatment Strategies

Trends in Endocrinology and Metabolism

Volumn 28, Issue 4, 2017, Pages 250-260

  Sunny, Nishanth E ^a   Bril, Fernando ^a   Cusi, Kenneth ^a,b  

^a UNIVERSITY OF FLORIDA   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

diabetes; fatty liver; glucagon like peptide 1; mitochondria; nonalcoholic steatohepatitis; obesity; pioglitazone

Indexed keywords

GLUCAGON LIKE PEPTIDE 1 RECEPTOR AGONIST; METFORMIN; PIOGLITAZONE; 2,4 THIAZOLIDINEDIONE DERIVATIVE; GLUCAGON LIKE PEPTIDE 1;

ADAPTATION; CITRIC ACID CYCLE; DISORDERS OF MITOCHONDRIAL FUNCTIONS; HEALTH HAZARD; HUMAN; LIFESTYLE MODIFICATION; MEDICATION THERAPY MANAGEMENT; MITOCHONDRIAL RESPIRATION; MITOCHONDRION; NON INSULIN DEPENDENT DIABETES MELLITUS; NONALCOHOLIC FATTY LIVER; NONHUMAN; OBESITY; OXIDATIVE STRESS; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; TARGET CELL; TREATMENT PLANNING; ANIMAL; FATTY LIVER; METABOLISM; PATHOLOGY;

ANIMALS; FATTY LIVER; GLUCAGON-LIKE PEPTIDE 1; HUMANS; MITOCHONDRIA; NON-ALCOHOLIC FATTY LIVER DISEASE; OBESITY; THIAZOLIDINEDIONES;

EID: 85008222802     PISSN: 10432760     EISSN: 18793061     Source Type: Journal    
DOI: 10.1016/j.tem.2016.11.006     Document Type: Review

References (87)

1. 1 Rinella, M.E., Nonalcoholic fatty liver disease: a systematic review. JAMA 313 (2015), 2263–2273.
2. 2 Cusi, K., Role of obesity and lipotoxicity in the development of nonalcoholic steatohepatitis: pathophysiology and clinical implications. Gastroenterology, 142, 2012 711-725.e6.
3. 3 Loomba, R., Sanyal, A.J., The global NAFLD epidemic. Nat. Rev. Gastroenterol. Hepatol. 10 (2013), 686–690.
4. 4 Ahmed, A., et al. Nonalcoholic fatty liver disease review: diagnosis, treatment, and outcomes. Clin. Gastroenterol. Hepatol. 13 (2015), 2062–2070.
5. 5 Armstrong, M.J., et al. Extrahepatic complications of nonalcoholic fatty liver disease. Hepatology 59 (2014), 1174–1197.
6. 6 Younossi, Z.M., et al. Association of nonalcoholic fatty liver disease (NAFLD) with hepatocellular carcinoma (HCC) in the United States from 2004 to 2009. Hepatology 62 (2015), 1723–1730.
7. 7 Bril, F. and Cusi, K. Management of nonalcoholic fatty liver disease in patients with type 2 diabetes mellitus: a call to action. Diabetes Care (in press).
8. 8 European Association for the Study of the Liver (EASL), European Association for the Study of Diabetes (EASD), European Association for the Study of Obesity (EASO)., EASL-EASD-EASO Clinical Practice Guidelines for the management of non-alcoholic fatty liver disease. Diabetologia 59 (2016), 1121–1140.
9. 9 Portillo-Sanchez, P., et al. High prevalence of nonalcoholic fatty liver disease in patients with type 2 diabetes mellitus and normal plasma aminotransferase levels. J. Clin. Endocrinol. Metab. 100 (2015), 2231–2238.
10. 10 Maximos, M., et al. The role of liver fat and insulin resistance as determinants of plasma aminotransferase elevation in nonalcoholic fatty liver disease. Hepatology 61 (2015), 153–160.
11. 11 Cusi, K., Treatment of patients with type 2 diabetes and non-alcoholic fatty liver disease: current approaches and future directions. Diabetologia 59 (2016), 1112–1120.
12. 12 Targher, G., et al. Prevalence of nonalcoholic fatty liver disease and its association with cardiovascular disease among type 2 diabetic patients. Diabetes Care 30 (2007), 1212–1218.
13. 13 Leite, N.C., et al. Histopathological stages of nonalcoholic fatty liver disease in type 2 diabetes: prevalences and correlated factors. Liver Int. 31 (2011), 700–706.
14. 14 Williamson, R.M., et al. Prevalence of and risk factors for hepatic steatosis and nonalcoholic fatty liver disease in people with type 2 diabetes: the Edinburgh Type 2 Diabetes Study. Diabetes Care 34 (2011), 1139–1144.
15. 15 Koehler, E.M., et al. Presence of diabetes mellitus and steatosis is associated with liver stiffness in a general population: The Rotterdam study. Hepatology 63 (2016), 138–147.
16. 16 Kwok, R., et al. Screening diabetic patients for non-alcoholic fatty liver disease with controlled attenuation parameter and liver stiffness measurements: a prospective cohort study. Gut 65 (2016), 1359–1368.
17. 17 Angulo, P., et al. Liver fibrosis, but no other histologic features, is associated with long-term outcomes of patients with nonalcoholic fatty liver disease. Gastroenterology, 149, 2015 389-397.e10.
18. 18 Bril, F., et al. Hepatic steatosis and insulin resistance, but not steatohepatitis, promote atherogenic dyslipidemia in NAFLD. J. Clin. Endocrinol. Metab. 101 (2016), 644–652.
19. 19 Bril, F., et al. Relationship between disease severity, hyperinsulinemia, and impaired insulin clearance in patients with nonalcoholic steatohepatitis. Hepatology 59 (2014), 2178–2187.
20. 20 Koliaki, C., et al. Adaptation of hepatic mitochondrial function in humans with non-alcoholic fatty liver is lost in steatohepatitis. Cell Metab. 21 (2015), 739–746.
21. 21 Patterson, R.E., et al. Lipotoxicity in steatohepatitis occurs despite an increase in tricarboxylic acid cycle activity. Am. J. Physiol. Endocrinol. Metab. 310 (2016), E484–E494.
22. 22 Donnelly, K.L., et al. Sources of fatty acids stored in liver and secreted via lipoproteins in patients with nonalcoholic fatty liver disease. J. Clin. Invest. 115 (2005), 1343–1351.
23. 23 Lambert, J.E., et al. Increased de novo lipogenesis is a distinct characteristic of individuals with nonalcoholic fatty liver disease. Gastroenterology 146 (2014), 726–735.
24. 24 Lomonaco, R., et al. Effect of adipose tissue insulin resistance on metabolic parameters and liver histology in obese patients with nonalcoholic fatty liver disease. Hepatology 55 (2012), 1389–1397.
25. 25 Satapati, S., et al. Elevated TCA cycle function in the pathology of diet-induced hepatic insulin resistance and fatty liver. J. Lipid Res. 53 (2012), 1080–1092.
26. 26 Satapati, S., et al. Mitochondrial metabolism mediates oxidative stress and inflammation in fatty liver. J. Clin. Invest. 125 (2015), 4447–4462.
27. 13C-octanoate breath test. Am. J. Gastroenterol. 98 (2003), 2335–2336.
28. 28 Iozzo, P., et al. Fatty acid metabolism in the liver, measured by positron emission tomography, is increased in obese individuals. Gastroenterology 139 (2010), 846–856 856.e1–e6.
29. 29 Sunny, N.E., et al. Excessive hepatic mitochondrial TCA cycle and gluconeogenesis in humans with nonalcoholic fatty liver disease. Cell Metab. 14 (2011), 804–810.
30. 30 Mehta, R., et al. The role of mitochondrial genomics in patients with non-alcoholic steatohepatitis (NASH). BMC Med. Genet., 17, 2016, 63.
31. 31 Sunny, N.E., et al. Progressive adaptation of hepatic ketogenesis in mice fed a high-fat diet. Am. J. Physiol. Endocrinol. Metab. 298 (2010), E1226–E1235.
32. 32 Cotter, D.G., et al. Ketogenesis prevents diet-induced fatty liver injury and hyperglycemia. J. Clin. Invest. 124 (2014), 5175–5190.
33. 33 Mannisto, V.T., et al. Ketone body production is differentially altered in steatosis and non-alcoholic steatohepatitis in obese humans. Liver Int. 35 (2015), 1853–1861.
34. 34 Cortez-Pinto, H., et al. Alterations in liver ATP homeostasis in human nonalcoholic steatohepatitis: a pilot study. JAMA 282 (1999), 1659–1664.
35. 35 Schmid, A.I., et al. Liver ATP synthesis is lower and relates to insulin sensitivity in patients with type 2 diabetes. Diabetes Care 34 (2011), 448–453.
36. 36 Abdelmalek, M.F., et al. Higher dietary fructose is associated with impaired hepatic adenosine triphosphate homeostasis in obese individuals with type 2 diabetes. Hepatology 56 (2012), 952–960.
37. 37 Szendroedi, J., et al. Abnormal hepatic energy homeostasis in type 2 diabetes. Hepatology 50 (2009), 1079–1086.
38. 38 Fritsch, M., et al. Time course of postprandial hepatic phosphorus metabolites in lean, obese, and type 2 diabetes patients. Am. J. Clin. Nutr. 102 (2015), 1051–1058.
39. 13C magnetic resonance spectroscopy. Nat. Med. 20 (2014), 98–102.
40. 13C] acetate. Nat. Med. 21 (2015), 108–109.
41. 41 Befroy, D.E., et al. Response to burgess. Nat. Med. 21 (2015), 109–110.
42. 42 Perry, R.J., et al. Propionate increases hepatic pyruvate cycling and anaplerosis and alters mitochondrial metabolism. J. Biol. Chem. 291 (2016), 12161–12170.
43. 43 Previs, S.F., Kelley, D.E., Tracer-based assessments of hepatic anaplerotic and TCA cycle flux: practicality, stoichiometry, and hidden assumptions. Am. J. Physiol. Endocrinol. Metab. 309 (2015), E727–E735.
44. 44 Perry, R.J., et al. The role of hepatic lipids in hepatic insulin resistance and type 2 diabetes. Nature 510 (2014), 84–91.
45. 45 Maceyka, M., Spiegel, S., Sphingolipid metabolites in inflammatory disease. Nature 510 (2014), 58–67.
46. 46 Perry, R.J., et al. Controlled-release mitochondrial protonophore reverses diabetes and steatohepatitis in rats. Science 347 (2015), 1253–1256.
47. 47 Machado, M.V., et al. Mouse models of diet-induced nonalcoholic steatohepatitis reproduce the heterogeneity of the human disease. PLoS One, 10, 2015, e0127991.
48. 48 Hannah, W.N. Jr., Harrison, S.A., Lifestyle and dietary interventions in the management of nonalcoholic fatty liver disease. Dig. Dis. Sci. 61 (2016), 1365–1374.
49. 49 Bacchi, E., et al. Both resistance training and aerobic training reduce hepatic fat content in type 2 diabetic subjects with NAFLD (The RAED2 randomized trial). Hepatology 58 (2013), 1287–1295.
50. 50 Haufe, S., et al. Randomized comparison of reduced fat and reduced carbohydrate hypocaloric diets on intrahepatic fat in overweight and obese human subjects. Hepatology 53 (2011), 1504–1514.
51. 51 Vilar-Gomez, E., et al. Weight loss through lifestyle modification significantly reduces features of nonalcoholic steatohepatitis. Gastroenterology, 149, 2015 367–378.e5, quiz e14–e15.
52. 52 Verbeek, J., et al. Roux-en-y gastric bypass attenuates hepatic mitochondrial dysfunction in mice with non-alcoholic steatohepatitis. Gut 64 (2015), 673–683.
53. 53 Toledo, F.G., et al. Mitochondrial capacity in skeletal muscle is not stimulated by weight loss despite increases in insulin action and decreases in intramyocellular lipid content. Diabetes 57 (2008), 987–994.
54. 54 Coen, P.M., et al. Exercise and weight loss improve muscle mitochondrial respiration, lipid partitioning, and insulin sensitivity after gastric bypass surgery. Diabetes 64 (2015), 3737–3750.
55. 55 Civitarese, A.E., et al. Calorie restriction increases muscle mitochondrial biogenesis in healthy humans. PLoS Med., 4, 2007, e76.
56. 56 Chalasani, N., et al. The diagnosis and management of non-alcoholic fatty liver disease: practice guideline by the American Gastroenterological Association, American Association for the Study of Liver Diseases, and American College of Gastroenterology. Gastroenterology 142 (2012), 1592–1609.
57. 57 Barb, D., et al. Pharmacological management of nonalcoholic fatty liver disease. Metabolism 65 (2016), 1183–1195.
58. 58 Belfort, R., et al. A placebo-controlled trial of pioglitazone in subjects with nonalcoholic steatohepatitis. N. Engl. J. Med. 355 (2006), 2297–2307.
59. 59 Sanyal, A.J., et al. Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis. N. Engl. J. Med. 362 (2010), 1675–1685.
60. 60 Cusi, K., et al. Long-term pioglitazone treatment for patients with nonalcoholic steatohepatitis and prediabetes or type 2 diabetes mellitus: a randomized trial. Ann. Intern. Med. 165 (2016), 305–315.
61. 61 Gastaldelli, A., et al. Importance of changes in adipose tissue insulin resistance to histological response during thiazolidinedione treatment of patients with nonalcoholic steatohepatitis. Hepatology 50 (2009), 1087–1093.
62. 62 Ratziu, V., et al. Rosiglitazone for nonalcoholic steatohepatitis: one-year results of the randomized placebo-controlled Fatty Liver Improvement with Rosiglitazone Therapy (FLIRT) Trial. Gastroenterology 135 (2008), 100–110.
63. 63 Ratziu, V., et al. Long-term efficacy of rosiglitazone in nonalcoholic steatohepatitis: results of the Fatty Liver Improvement by Rosiglitazone Therapy (FLIRT 2) extension trial. Hepatology 51 (2010), 445–453.
64. 64 Rabol, R., et al. Opposite effects of pioglitazone and rosiglitazone on mitochondrial respiration in skeletal muscle of patients with type 2 diabetes. Diabetes Obes. Metab. 12 (2010), 806–814.
65. 65 Caldwell, S.H., et al. The effects of 48 weeks of rosiglitazone on hepatocyte mitochondria in human nonalcoholic steatohepatitis. Hepatology 46 (2007), 1101–1107.
66. 66 Brunmair, B., et al. Thiazolidinediones, like metformin, inhibit respiratory complex I: a common mechanism contributing to their antidiabetic actions?. Diabetes 53 (2004), 1052–1059.
67. 67 Sanz, M.N., et al. Acute mitochondrial actions of glitazones on the liver: a crucial parameter for their antidiabetic properties. Cell. Physiol. Biochem. 28 (2011), 899–910.
68. 68 Divakaruni, A.S., et al. Thiazolidinediones are acute, specific inhibitors of the mitochondrial pyruvate carrier. Proc. Natl. Acad. Sci. U.S.A. 110 (2013), 5422–5427.
69. 69 Colca, J.R., et al. Identification of a mitochondrial target of thiazolidinedione insulin sensitizers (mTOT) – relationship to newly identified mitochondrial pyruvate carrier proteins. PLoS One, 8, 2013, e61551.
70. 70 LeBrasseur, N.K., et al. Thiazolidinediones can rapidly activate AMP-activated protein kinase in mammalian tissues. Am. J. Physiol. Endocrinol. Metab. 291 (2006), E175–E181.
71. 71 Bogacka, I., et al. Pioglitazone induces mitochondrial biogenesis in human subcutaneous adipose tissue in vivo. Diabetes 54 (2005), 1392–1399.
72. 72 Skov, V., et al. Pioglitazone enhances mitochondrial biogenesis and ribosomal protein biosynthesis in skeletal muscle in polycystic ovary syndrome. PLoS One, 3, 2008, e2466.
73. 73 (2016) Standards of Medical Care in Diabetes-2016: Summary of Revisions. Diabetes Care 39 (Suppl 1), S4-S5.
74. 74 Cusi, K., et al. Metabolic effects of metformin on glucose and lactate metabolism in noninsulin-dependent diabetes mellitus. J. Clin. Endocrinol. Metab. 81 (1996), 4059–4067.
75. 75 Owen, M.R., et al. Evidence that metformin exerts its anti-diabetic effects through inhibition of complex 1 of the mitochondrial respiratory chain. Biochem. J. 348:Pt 3 (2000), 607–614.
76. 76 Campins, L., et al. Oral drugs related with muscle wasting and sarcopenia. A review. Pharmacology 99:1–2 (2016), 1–8.
77. 77 Ferrannini, E., The target of metformin in type 2 diabetes. N. Engl. J. Med. 371 (2014), 1547–1548.
78. 78 Madiraju, A.K., et al. Metformin suppresses gluconeogenesis by inhibiting mitochondrial glycerophosphate dehydrogenase. Nature 510 (2014), 542–546.
79. 79 Bugianesi, E., et al. A randomized controlled trial of metformin versus vitamin E or prescriptive diet in nonalcoholic fatty liver disease. Am. J. Gastroenterol. 100 (2005), 1082–1090.
80. 80 Lavine, J.E., et al. Effect of vitamin E or metformin for treatment of nonalcoholic fatty liver disease in children and adolescents: the TONIC randomized controlled trial. JAMA 305 (2011), 1659–1668.
81. 81 Marso, S.P., et al. Liraglutide and cardiovascular outcomes in type 2 diabetes. N. Engl. J. Med. 375 (2016), 311–322.
82. 82 Trujillo, J.M., et al. GLP-1 receptor agonists: a review of head-to-head clinical studies. Ther. Adv. Endocrinol. Metab. 6 (2015), 19–28.
83. 83 Armstrong, M.J., et al. Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study. Lancet 387 (2016), 679–690.
84. 84 Armstrong, M.J., et al. Glucagon-like peptide 1 decreases lipotoxicity in non-alcoholic steatohepatitis. J. Hepatol. 64 (2016), 399–408.
85. 85 Lee, J., et al. Exendin-4 improves steatohepatitis by increasing Sirt1 expression in high-fat diet-induced obese C57BL/6J mice. PLoS One, 7, 2012, e31394.
86. 86 Xu, F., et al. SIRT1 mediates the effect of GLP-1 receptor agonist exenatide on ameliorating hepatic steatosis. Diabetes 63 (2014), 3637–3646.
87. 13C magnetic resonance spectroscopy. Cell Metab. 24 (2016), 167–171.